Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy

This work reports the surface functionalization of polymeric PLGA nanoparticles by non-covalent insertion of a homo-bifunctional chemical crosslinker, bis(sulfosuccinimidyl) suberate (BS3) for targeted cancer therapy. We dissolved BS3 in aqueous solution of PVA during formulation of nanoparticles by a modified solid/oil/water emulsion solvent evaporation method. The non-covalent insertion of BS3 was confirmed by Fourier transform infrared (FTIR) spectroscopy. Curcumin and annexin A2 were used as a model drug and a cell specific target, respectively. Nanoparticles were characterized for particle size, zeta potential and surface morphology. The qualitative assessment of antibody attachment was performed by transmission electron microscopy (TEM) as well as confocal microscopy. The optimized formulation showed antibody attachment of 86%. However, antibody attachment was abolished upon blocking the functional groups of BS3. The availability of functional antibodies was evaluated by the presence of a light chain fraction after gel electrophoresis. We further evaluated the in vitro release kinetics of curcumin from antibody coated and uncoated nanoparticles. The release of curcumin is enhanced upon antibody attachment and followed an anomalous release pattern. We also observed that the cellular uptake of nanoparticles was significantly higher in annexin A2 positive cells than in negative cells. Therefore, these results demonstrate the potential use of this method for functionalization as well as to deliver chemotherapeutic agents for treating cancer.

[1]  R. Ownbey,et al.  Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. , 2010, Experimental and molecular pathology.

[2]  A. Protopopov,et al.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. , 2009, Blood.

[3]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[4]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[5]  Robert Gurny,et al.  Current methods for attaching targeting ligands to liposomes and nanoparticles. , 2004, Journal of pharmaceutical sciences.

[6]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[7]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  S. Ferreira,et al.  Box-Behnken design: an alternative for the optimization of analytical methods. , 2007, Analytica chimica acta.

[9]  Koning,et al.  Immunoliposomes for the targeted delivery of antitumor drugs. , 1999, Advanced drug delivery reviews.

[10]  Gabriel A Silva,et al.  Characterization of the functional binding properties of antibody conjugated quantum dots. , 2007, Nano letters.

[11]  G. Ertan,et al.  Extended release lipophilic indomethacin microspheres: formulation factors and mathematical equations fitted drug release rates. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  S. Sahoo,et al.  Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. , 2009, Nanomedicine.

[13]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[14]  T. Allen Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[15]  L. Brannon-Peppas,et al.  PEGylation strategies for active targeting of PLA/PLGA nanoparticles. , 2009, Journal of biomedical materials research. Part A.

[16]  M. R. Kumar,et al.  Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[18]  C. F. van der Walle,et al.  Engineering biodegradable polyester particles with specific drug targeting and drug release properties. , 2008, Journal of pharmaceutical sciences.

[19]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[20]  Mahesh C Sharma,et al.  The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. , 2007, Current pharmaceutical design.

[21]  F. Marcucci,et al.  Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. , 2004, Drug discovery today.

[22]  D. Scheinberg,et al.  Conscripts of the infinite armada: systemic cancer therapy using nanomaterials , 2010, Nature Reviews Clinical Oncology.

[23]  Robert Gurny,et al.  Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. , 2003, International journal of pharmaceutics.